Neoadjuvant Adebrelimab With Dalpiciclib for Resectable Esophageal Squamous Cell Carcinomas

NCT06225921 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

6

Enrollment

OTHER

Sponsor class

Conditions

Esophageal Squamous Cell Carcinoma

Interventions

DRUG: Adebrelimab
DRUG: Dalpiciclib 100mg
DRUG: Dalpiciclib 150mg

Sponsor

West China Hospital